Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease

European Journal of Medicinal Chemistry

Volumn 46, Issue 6, 2011, Pages 2170-2184

  Tasso, B ^a   Catto, M ^b   Nicolotti, O ^b   Novelli, F ^a   Tonelli, M ^a   Giangreco, I ^b   Pisani, L ^b   Sparatore, A ^c   Boido, V ^a   Carotti, A ^b   Sparatore, F ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Acetylcholinesterase inhibitors; Bi and tricyclic systems derivatives; Butyrylcholinesterase inhibitors; Quinolizidine derivatives; Single entity multi target agents

Indexed keywords

1,1 DIPHENYL 2 [(OCTAHYDRO 1H QUINOLIZIN 1 YL)] ETHANE; 10 (9 ANTHRYLCARBONYL)PHENOTHIAZINE; 10 [1 AZABICYCLO(2,2,2)OCT 3 YL] PHENOTHIAZINE; 2 [(OCTAHYDRO 1H QUINOLIZIN 1 YL)METHYLTHIO] 1 (10H PHENOTHIAZIN 10 YL)PROPAN 1 ONE; 2 [[(OCTAHYDRO 2H QUINOLIZIN 1 YL)METHYL]THIO] ACETAMIDE; 2 [[(OCTAHYDRO 2H QUINOLIZIN 1 YL)METHYL]THIO] ETHAN 1 AMINE; 5 METHYL 1 (9H THIOXANTHEN 9 YLMETHYL) OCTAHYDROQUINOLIZINIUM IODIDE; 9 [(OCTAHYDRO 1H QUINOLIZIN 1 YL)METHYL] 9H CARBAZOLE; ACETYLCHOLINESTERASE; AMINOPEPTIDASE; ASTRA 1397; AUTORECEPTOR; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; HEPTYLSTIGMINE TARTRATE; LUPININE; MEPACRINE; METIXENE; MF 8622; MUSCARINIC RECEPTOR; N [(OCTAHYDRO 1H QUINOLIZIN 1H YL)METHYL] N PHENYLANILINE; PERICIAZINE; PROFENAMINE; QUINOLIZIDINE DERIVATIVE; RIVASTIGMINE; TACRINE; TRIFLUPROMAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ARTICLE; DRUG ACTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; ERYTHROCYTE; HUMAN; HUMAN CELL; IC 50; MOLECULAR DOCKING;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; ANIMALS; BUTYRYLCHOLINESTERASE; CATTLE; CHOLINESTERASE INHIBITORS; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; QUINOLIZIDINES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79955606915     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2011.02.071     Document Type: Article

References (93)

1. (a) R. Jakob-Roetne, H. Jacobsen, Angew. Chem. Int. Ed. 48 (2009) 3030-3059;
2. (b) A. Rauk, Chem. Soc. Rev. 38 (2009) 2698-2715;
3. (c) H.C. Huang, Z.F. Jiang, J. Alzheimer's Dis. 16 (2009) 15-27.
4. (a) M. Citron, Nat. Rev. Drug Discov. 9 (2010) 387-398;
5. (b) M.N. Sabbagh, Am. J. Geriatr. Pharmacother. 7 (2009) 167-185.
6. V. Tumiatti, M.L. Bolognesi, A. Minarini, M. Rosini, A. Milelli, R. Matera, C. Melchiorre, Exp. Opin. Ther. Patents 18 (2008) 387-401.
7. (a) M.M. Mesulam, A. Guillozet, P. Shaw, B. Quinn, Neurobiol. Dis. 9 (2002) 88-93;
8. (b) S. Darvesh, D.A. Hopkins, C. Geula, Nat. Rev. Neurosci. 4 (2003) 131-138.
9. E. Giacobini, Drugs Aging 18 (2001) 891-898.
10. N.H. Greig, T. Utsuki, Q.-S. Yu, X. Zhu, H.W. Holloway, T.A. Perry, B. Lee, D.K. Ingram, D.K. Lahiri, Curr. Med. Res. Opin. 17 (2001) 159-165.
11. E. Giacobini, Butyrylcholinesterase - Its Function and Inhibitors. Martin Dunitz, London, 2003.
12. (a) C.J. Van der Schyf, W.J. Geldenhuys, M.B.H. Youdin, Drugs Fut. 31 (2006) 447-460;
13. (b) A. Cavalli, M.L. Bolognesi, A. Minarini, M. Rosini, C. Melchiorre, J. Med. Chem. 51 (2008) 347-372;
14. (c) M.L. Bolognesi, M. Rosini, V. Andrisano, M. Bartolini, A. Minarini, V. Tumiatti, C. Melchiorre, Curr. Pharm. Des. 15 (2009) 601-613;
15. (d) A. Carotti, ACS-EFMC Meeting, Frontiers in CNS and Oncology Medicinal Chemistry. COMC-059, Siena, Italy, October 7-9 2007.
16. H. Sugimoto, H. Ogura, Y. Arai, Y. Jimura, Y. Yamanishi, Jpn. J. Pharmacol. 89 (2002) 7-20.
17. (a) J. Marco-Contelles, M. do Carmo Carreiras, C. Rodriguez, M. Villarroya, A.G. Garcia, Chem. Rev. 106 (2006) 116-133;
18. (b) R. Bullock, Exp. Rev. Neurother. 4 (2004) 153-163.
19. (a) C.M. Spencer, S. Noble, Rivastigmine. Drugs Aging 13 (1998) 391-411;
20. (b) L. Bartorelli, C. Giraldi, M. Saccardo, S. Cammarata, G. Bottini, M. Fasanaro, A. Trequattrini, Curr. Med. Res. Opin. 21 (2005) 1809-1817;
21. (c) A. Enz, R. Amstutz, H. Boddeke, G. Gmelin, J. Malanowski, Progr. Brain Res. 98 (1993) 431-438.
22. (a) F.H. Shaw, G.A. Bentley, Aust. J. Exp. Biol. Med. Sci. 31 (1953) 573-576;
23. (b) P.N. Kaul, J. Pharm. Pharmacol. 14 (1962) 243-248;
24. (c) M. Brufani, L. Filocamo, S. Lappa, A. Maggi, Drugs Fut. 22 (1997) 397-410;
25. (d) N. Qizilbash, A. Whitehead, J. Higgins, G. Wilcock, L. Schneider, M. Farlow, J. Am. Med. Assoc. 280 (1998) 1777-1782.
26. (a) P. De Sarno, M. Pomponi, E. Giacobini, X.C. Tang, E. Williams, Neurochem. Res. 14 (1989) 971-977;
27. (b) B.P. Imbimbo, P. Martelli, W.M. Troetel, F. Lucchelli, U. Lucca, L.J. Thal, Neurology 52 (1999) 700-708.
28. (a) B. Reisberg, R. Doody, A. Stöffler, F. Schmitt, S. Ferris, H.J. Möbius, N. Engl. J. Med. 348 (2003) 1333-1341;
29. (b) R. Blesa, Eur. Neurol. Rev. 3 (2008) 22-27;
30. (c) H. Kavirayan, Exp. Opin. Drug Saf. 8 (2009) 89-109.
31. (a) Q. Yu, H.W. Holloway, T. Utsuki, A. Brossi, N.H. Greig, J. Med. Chem. 42 (1999) 1855-1861;
32. (b) Q. Yu, H.W. Holloway, J.L. Flippen-Anderson, B. Hoffman, A. Brossi, N.H. Greig, J. Med. Chem. 44 (2001) 4062-4071.
33. E. Giacobini, P.L. Griffini, T. Maggi, et al., Soc. Neurosci. Abstr. 22 (1996) 203.
34. (a) B.J. Bayliss, A. Todrick, Biochem. J. 62 (1956) 62-67;
35. (b) A. Saxena, A.M. Redman, X. Jiang, O. Lockridge, B.P. Doctor, Biochemistry 36 (1997) 14642-14651.
36. (a) R. Dahlbom, T. Ekstrand, Acta Chem. Scand. 5 (1951) 102-114;
37. (b) K.B. Augustinsson, Scand. J. Lab. Clin. Med. 7 (1955) 284-290;
38. (c) K.B. Augustinsson, H. Eriksson, Y. Faijersson, Clin. Chim. Acta 89 (1978) 239-252;
39. (d) P.W. Elsinghorst, C.M. Gonzales Tanarro, M. Gütschow, J. Med. Chem. 49 (2006) 7540-7544.
40. S. Darvesh, R.S. McDonald, K.V. Darvesh, D. Mataija, S. Conrad, J. Gomez, R. Walsh, E. Martin, Bioorg. Med. Chem. 13 (2007) 6367-6378.
41. S. Darvesh, R.S. McDonald, A. Penwell, S. Conrad, K.V. Darvesh, D. Mataija, G. Gomez, A. Caines, R. Walsh, E. Martin, Bioorg. Med. Chem. 13 (2005) 211-222.
42. (a) C. Bruhlmann, F. Ooms, P.A. Carrupt, B. Testa, M. Catto, F. Leonetti, C. Altomare, A. Carotti, J. Med. Chem. 44 (2001) 3195-3198;
43. (b) L. Leonetti, A. Cappa, C. Maccallini, A. Carotti, Arkivoc (2004) 272-285;
44. (c) F. Leonetti, M. Catto, O. Nicolotti, L. Pisani, A. Cappa, A. Stefanachi, A. Carotti, Bioorg. Med. Chem. 16 (2008) 7450-7456;
45. (d) L. Pisani, M. Catto, I. Giangreco, L. Leonetti, O. Nicolotti, A. Stefanachi, S. Cellamare, A. Carotti, Chem. Med. Chem. 5 (2010) 1616-1630.
46. (a) L. Piazzi, A. Cavalli, F. Belluti, A. Bisi, S. Gobbi, S. Rizzo, M. Bartolini, V. Andrisano, M. Recanatini, A. Rampa, J. Med. Chem. 50 (2007) 4250-4254;
47. (b) S. Rizzo, A. Cavalli, L. Ceccarini, M. Bartolini, F. Belluti, A. Bisi, V. Andrisano, M. Recanatini, A. Rampa, Chem. Med. Chem. 4 (2009) 670-679.
48. K. Saito, et al., Unpublished data cited in S. Ohmiya, K. Saito, I. Murakashi, Lupine alkaloids; in: G.A. Cordell (Ed.), "The Alkaloids", Academic Press, San Diego 1995, vol. 47, pp. 25-114.
49. E.V. Rozengart, Dokl. Biochem. Biophys. 388 (2003) 39-42.
50. (a) W.H. Timberlake, R.S. Schwab, New Engl. J. Med. 247 (1952) 98-100;
51. (b) M.E. Farquharson, R.G. Johnston, Br. J. Pharmacol. 14 (1959) 559-566.
52. (a) P.V. Petersen, N. Lassen, T. Holm, R. Kopf, I. Møller Nielsen, Arzneim. Forsch. 8 (1958) 395-397;
53. (b) R. Caviezel, E. Eichenberger, H. Kidder, H. Lauener, G. Stille, Arch. Int. Pharmacodyn. 14 (1963) 331-356.
54. H.L. Yale, F. Sowinski, J. Bernstein, J. Am. Chem. Soc. 79 (1957) 4375-4379.
55. (a) U. Spiegelberg, G. Kleu, Arzneim. Forsch. 17 (1967) 159-172;
56. (b) A. Vialla, Encéphale 58 (1969) 3-7.
57. R. Dahlbom, Sci. Repts. Ist. Sup. Sanità 2 (1962) 309-319.
58. (a) H. Waelsch, D. Nachmansohn, Proc. Soc. Exp. Biol. Med. 54 (1943) 336-338;
59. (b) D. Nachmansohn, H. Schneemann, J. Biol. Chem. 159 (1945) 239-240;
60. (c) G.J. Wright, J.C. Sabine, J. Pharmacol. Exp. Ther. 93 (1948) 230-239.
61. F. Sparatore, Ann. Chim. 52 (1962) 271-277.
62. F. Sparatore, V. Boido, Ann. Chim. 54 (1964) 591-601.
63. V. Boido, F. Sparatore, Ann. Chim. 56 (1966) 1606-1613.
64. V. Boido, A. Sparatore, Farmaco, Ed. Sci. 37 (1982) 63-73.
65. A. Sparatore, M. Veronese, F. Sparatore, Farmaco, Ed. Sci. 42 (1987) 159-174.
66. A. Sparatore, V. Boido, F. Sparatore, Farmaco 44 (1989) 1193-1203.
67. C. Boido Canu, V. Boido, F. Sparatore, Boll. Chim. Farm. 128 (1989) 212-215.
68. I. Vazzana, F. Novelli, F. Sparatore, A. Sparatore, G. Fadda, C. Manca, Farmaco 49 (1994) 105-110.
69. F. Novelli, B. Tasso, F. Sparatore, Farmaco 54 (1999) 354-358.
70. F. Novelli, A. Sparatore, B. Tasso, F. Sparatore, Bioorg. Med. Chem. Lett. 9 (1999) 3031-3034.
71. B. Tasso, A. Sparatore, F. Sparatore, Farmaco 58 (2003) 669-676.
72. V. Villa, M. Tonelli, S. Thellung, A. Corsaro, B. Tasso, F. Novelli, C. Canu, K. Chiovitti, D. Paludi, C. Russo, A. Sparatore, A. Aceto, V. Boido, F. Sparatore, T. Florio, Neurotoxicity Res. (2010). doi:10.1007/s12640-010-9189-8.
73. (a) C. Gueremy, R. Labey, D. Wirth, M. Auclair, Phenothiazine derivatives. US Patent. 1976, 3987042 A1;
74. (b) C.A. Grob, A. Kaiser, E. Renk, Helv. Chim. Acta 40 (1957) 2170-2185.
75. F. Novelli, F. Sparatore, Farmaco 48 (1993) 1021-1049.
76. G.R. Clemo, J. Rudinger, J. Chem. Soc. (1951) 2714-2718.
77. F. Sparatore, V. Boido, P. Preziosi, E. Miele, G. De Natale, Farmaco Ed. Sci. 24 (1969) 589-621.
78. G.L. Ellman, D. Courtney, V. Andres Jr., R.M. Featherstone, Biochem. Pharmacol. 7 (1961) 88-95.
79. M.L. Verdonk, J.C. Cole, M.J. Hartshorn, C.W. Murray, R.D. Taylor, Improved protein-ligand docking using GOLD, Proteins 52 (2003) 609-623. (Pubitemid 37034158)
80. (a) Z. Radic, N.A. Pickering, D.C. Vellom, S. Camp, P. Taylor, Biochemistry 32 (1993) 12074-12084;
81. (b) J. Debord, L. Merle, J.-C. Bollinger, T. Dantoine, J. Enzym. Inhib. Med. Chem. 17 (2002) 197-202.
82. (a) P.R. Carlier, Y.F. Han, E.S.H. Chow, C.P. Li, H. Wang, T.X. Lieu, H.S. Wong, Y.P. Pang, Bioorg. Med. Chem. 7 (1999) 351-357;
83. (b) P.R. Carlier, E.S.H. Chow, Y. Han, J. Liu, Y. El Yazal, Y.P. Pang, J. Med. Chem. 42 (1999) 4225-4231;
84. (c) G. Campiani, C. Fattorusso, S. Butini, A. Gaeta, M. Agnusdei, S. Gemma, M. Persico, B. Catalanotti, L. Savini, V. Nacci, E. Novellino, H.W. Holloway, N.H. Greig, T. Belinskaya, G.M. Fedorko, A. Saxena, J. Med. Chem. 48 (2005) 1919-1929;
85. (d) P.W. Elsinghorst, J.S. Cieslik, K. Mohr, C. Tränkle, M. Gütschow, J. Med. Chem. 50 (2007) 5685-5695;
86. (e) J.H.M. Lange, H.K.A.C. Coolen, M.A.W. Van der Neut, A.J.M. Borst, B. Stork, P.C. Verveer, C.G. Cruse, J. Med. Chem. 53 (2010) 1338-1346.
87. A. Sparatore, A.M. Caviglia, M. Marchi, M. Raiteri, Pharmacological characterization of the presynaptic muscarinic autoreceptors regulating acetylcholine release from rat cortical synaptosomes. in: G. Biggio, P.F. Spano, G. Toffano, G.L. Sessa (Eds.), Symposia in Neuroscience. III. Modulation of Central and Peripheral Transmitter Function. Liviana Press, Padova, 1986, pp. 447-452.
88. (a) C.M. Baratti, J.W. Opezzo, S.R. Kopf, Behav. Neural Biol. 60 (1993) 69-74;
89. (b) W.B. Rowe, J.-P. O'Donnell, D. Pearson, G.M. Rose, M.J. Meaney, R. Quirion, Behav. Brain Res. 145 (2003) 171-178;
90. (c) C.C. Felder, F.P. Bymaster, J. Ward, N. DeLapp, J. Med. Chem. 43 (2000) 4333-4353.
91. R. Dahlbom, H. Diamant, T. Edlund, T. Ekstrand, B. Holmstedt, Acta Pharmacol. Toxicol. 9 (1953) 163-167.
92. A.D. Mosnaim, J. Puente, R. Saavedra, S. Diamond, M.E. Wolf, Pharmacology 67 (2003) 6-13.
93. M.J. Hartshorn, M.L. Verdonk, G. Chessari, S.C. Brewerton, W.T.M. Mooij, P.N. Mortenson, C.W. Murray, J. Med. Chem. 50 (2007) 726-741.